Latest news

• Elan buys into GSK-partnered Theravance programmes for $1bn

  Aside from Breo ( known as Relvar outside the US), Elan will get royalties on sales of COPD combination therapy Anoro ( umeclidinium bromide and vilanterol), vilanterol as a monotherapy and GSK961081, a

• GSK trial throws everything at COPD

  All three drugs will be delivering via GSK's Ellipta inhaler, which is already used in the company's recently introduced dual therapies Anoro ( umeclidinium and vilanterol) and Relvar/Breo ( fluticasone furoate and vilanterol).

• SMC: Celgene's Abraxane 'too expensive' for Scotland

  SMC: Celgene's Abraxane 'too expensive' for Scotland. But medicines watchdog backs Sovaldi, Invokana, Defitelio, Relvar Ellipta. ... Drugs that received positive opinions included Janssen's Invokana ( canagliflozin) for type 2 diabetes, Jazz

• GSK clear to launch COPD hope Anoro in Europe

  Strengthens respiratory platform ahead of patent expiry for Advair/Seretide

• Breo off to slow start in US as Advair slips, says GSK

  First-quarter turnover came in at £5.6bn ( $9.5bn), with Advair sliding 15 per cent to £1.04bn - dragging down US sales by 10 per cent - while Breo ( known as Relvar in some